Regeneron Pharmaceuticals, Inc. · REGN · Next earnings

Regeneron Pharmaceuticals, Inc. reports Thursday, Jan 28, 2027

REGN reports before market open with consensus EPS at $25.30 and revenue at $5.85B. Last quarter: Regeneron posts strong Q3 growth as pipeline expands

Reports Before market open85 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $25.30 Calendar consensus
Consensus revenue $5.85B Calendar consensus
Report date Jan 28, 2027 Thursday, date estimated
Session Before market open 85 days away

Where REGN left off: FY2026 Q3

Full report

Regeneron posts strong Q3 growth as pipeline expands

EPS surprise +21.6% Reported $20.07 vs $16.51
Revenue surprise +11.6% Reported $5.12B vs $4.58B
Stock move +13.3% Event window
Subsequent drift 0.0% Up to 20 sessions

Management's guidance sentiment remained maintained; the current analysis notes modest refinements to 2026 guidance and anticipates higher R&D spending in 2027.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Regulatory approvals remain pending for cemdisiran and the EYLEA HD prefilled syringe.
  • Biosimilar and pricing pressure could affect the ophthalmology franchise.
  • The business remains reliant on Sanofi collaboration revenue.
  • Launching multiple assets across therapeutic areas creates execution risk.

Questions analysts left open

  • Competitive positioning of CIDEB siRNA against other NASH approaches.
  • Launch strategy and patient uptake for cemdisiran.
  • Differentiation of next-generation Dupixent assets against emerging competitors.
  • Potential switching dynamics in PNH and the effect of EYLEA biosimilars.

Ask FN2 about REGN next report

Transcript, numbers and history already loaded
What should I watch for in REGN's next earnings report?How did REGN guide last quarter, and is consensus above or below that?Give me the bull and bear case going into REGN earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the REGN recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent REGN quarters

All REGN earnings
+13.3%FY2026 Q3+6.2%FY2026 Q2-6.2%FY2026 Q1-1.1%FY2025 Q4

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q3

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.